The Biomedical Advanced Research and Development Authority (BARDA) is pumping the additional cash into the advancement of Summit’s precision drug ridinilazole
(NASDAQ:SMMT) () said the American authorities have increased their financial backing of a programme developing a next-generation antibiotic.
The Biomedical Advanced Research and Development Authority (BARDA) is pumping a further US$8.8mln into the advancement of Summit’s precision drug ridinilazole for the treatment of C. difficile infection () taking the total value of the award to US$72.5mln.
The latest US cash injection will support a new clinical trial in adolescent patients, which in turn is expected to help with the new drug application for ridinilazole.
“BARDA’s continued support for ridinilazole is instrumental in helping to bring this potential CDI treatment option to patients, whose current treatment options fail to sustain cures for one third of the population,” said Summit Glyn Edwards.
“We thank BARDA for its commitment to ridinilazole, innovation and public health,” he added.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE